Loading peptide profile…
Loading peptide profile…
LY3841136
Eloralintide is an investigational drug in development for obesity. It acts mainly on the amylin type 1 receptor. In a 48-week phase 2 trial of 263 adults with obesity or overweight and no type 2 diabetes, average weight fell 9% to 20% across treated groups, against 0.4% on placebo.
Not FDA approved, research use onlyHow we review these guides5 research sources
In cell assays it preferentially activated the human amylin type 1 receptor over the calcitonin receptor and the amylin type 3 receptor.
Lowered food intake and body weight, mainly through fat loss, in diet-induced obese rats, with less taste avoidance than cagrilintide in lean rats.
In a 48-week placebo-controlled trial of 263 adults, average weight fell 9% to 20% across treated groups, against 0.4% on placebo.
Phase 1 studies in 48 healthy people and 100 people with obesity or overweight reported weight reductions and mostly mild adverse events.
No. This profile records Eloralintide as not FDA approved and for research use only. Review the regulatory and source details on this page for the current context.
This guide links to 5 curated or current research sources. Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Review the Eloralintide research sourcesReported side effects of Eloralintide include Nausea, Fatigue, Decreased appetite, Headache, Diarrhea, and Vomiting. They are reported or occasional reactions, not a prediction of what any one person will experience.
Reported as generally well tolerated in a Lilly-funded 48-week trial, where nausea and fatigue were most common. One serious event in a 100-person phase 1 study was judged unrelated. A 2026 analysis called the class's data sparse and low certainty. Safety depends on dose, sourcing, health history and medical supervision, so this page does not call it safe for personal use.
Market evidence
We have not assessed certificate coverage for Eloralintide yet. Research on this page describes the molecule. Vendor certificates concern particular market samples or batches; they do not change the research evidence or establish clinical safety, sterility, or suitability for use.
The clinic network
Request a free connection to a peptide clinic, by telehealth or in person. A licensed clinician decides whether any treatment is right for you. What peptide therapy involves
NNMT-blocking small molecule tested in cells and obese mice
from $0.65/mg · 143 vendorsNº 001 / 006Synthetic gastric peptide studied almost entirely in animals
from $1.10/mg · 241 vendorsNº 002 / 006Short-acting GHRH analog without its own human trials
from $2.65/mg · 118 vendorsNº 003 / 006Synthetic pineal tetrapeptide from one research lineage
from $0.45/mg · 155 vendorsNº 004 / 006Mitochondrial peptide studied in mice and cells, not FDA-approved
from $1.20/mg · 231 vendorsNº 006 / 006Unapproved melanocortin agonist with only pilot and case-report data
from $1.30/mg · 112 vendorsNº 005 / 006